title: [Treatment of acid-related diseases of the gastrointestinal tract. Observations in patients receiving a single evening dose of 300 mg ranitidine].
abstract: Testing of the effectiveness and tolerability of ranitidine treatment in acid-related diseases of the gastrointestinal tract in non-selected outpatients.
  
  
  METHODS
  Observations made by 15,180 general practitioners and internists in the Länder of former West Germany in the period January 1989 to December 1990.
  
  
  METHODS
  23,783 patients with acid-related diseases of the gastrointestinal tract for which treatment with ranitidine is indicated (no further diagnostic or therapeutic requirement).
  
  
  METHODS
  300 mg ranitidine administered in the form of a single evening dose.
  
  
  RESULTS
  A duodenal ulcer presented in 50.1%, a gastric ulcer in 26%, and reflux esophagitis in 29.6% of the patients; in 17.5% some other gastrointestinal disease (for the most part gastritis) was diagnosed. Six weeks of treatment was associated with a high rate of healing (more than 90%). The total incidence of side effects was a very low 0.77% (183 cases). These results confirm the effectiveness and good tolerability of ranitidine.
authors.affiliation: Institut für Allgemeine Pharmakologie, Medizinischen Hochschule, Hannover.
authors.forename: K F
authors.initials: KF
authors.lastname: Sewing
authors.forename: E
authors.initials: E
authors.lastname: Franz
mesh_terms: D000328:Adult; D000368:Aged; D004334:Drug Administration Schedule; D004381:Duodenal Ulcer / Q000188:drug therapy; D004942:Esophagitis, Peptic / Q000188:drug therapy; D005260:Female; D005756:Gastritis / Q000188:drug therapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D010437:Peptic Ulcer / Q000188:drug therapy*; D011899:Ranitidine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D011899:Ranitidine
vernacular_title: Behandlung säurebedingter Erkrankungen des Gastrointestinaltrakts. Eine Anwendungsbeobachtung mit abendlicher Einmalgabe von 300 mg Ranitidin.